AbbVie Inc. (ABBV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABBV POWR Grades
- Quality is the dimension where ABBV ranks best; there it ranks ahead of 97.76% of US stocks.
- The strongest trend for ABBV is in Quality, which has been heading up over the past 179 days.
- ABBV ranks lowest in Momentum; there it ranks in the 11th percentile.
ABBV Stock Summary
- ABBVIE INC's market capitalization of $237,296,230,594 is ahead of 99.51% of US-listed equities.
- ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.62% of US stocks.
- The volatility of ABBVIE INC's share price is greater than that of only 8.54% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to ABBV, based on their financial statements, market capitalization, and price volatility, are NVO, BABA, PFE, TMO, and DHR.
- ABBV's SEC filings can be seen here. And to visit ABBVIE INC's official web site, go to www.abbvie.com.
ABBV Valuation Summary
- In comparison to the median Healthcare stock, ABBV's price/earnings ratio is 2.04% higher, now standing at 20.
- Over the past 118 months, ABBV's EV/EBIT ratio has gone up 4.4.
Below are key valuation metrics over time for ABBV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABBV | 2022-09-23 | 4.4 | 17.3 | 20.0 | 19.5 |
| ABBV | 2022-09-22 | 4.4 | 17.3 | 20.0 | 19.5 |
| ABBV | 2022-09-21 | 4.3 | 16.9 | 19.6 | 19.2 |
| ABBV | 2022-09-20 | 4.4 | 17.1 | 19.8 | 19.3 |
| ABBV | 2022-09-19 | 4.4 | 17.2 | 20.0 | 19.4 |
| ABBV | 2022-09-16 | 4.4 | 17.4 | 20.2 | 19.6 |
ABBV Growth Metrics
- Its 5 year cash and equivalents growth rate is now at 706.71%.
- The 4 year net income to common stockholders growth rate now stands at 41.71%.
- The 3 year cash and equivalents growth rate now stands at 24.53%.
The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 57,349 | 22,923 | 12,637 |
| 2022-03-31 | 56,725 | 22,808 | 12,479 |
| 2021-12-31 | 56,197 | 22,777 | 11,542 |
| 2021-09-30 | 55,169 | 22,556 | 7,534 |
| 2021-06-30 | 53,729 | 20,451 | 6,663 |
| 2021-03-31 | 50,195 | 18,650 | 5,159 |
ABBV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
- ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
- PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.
The table below shows ABBV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.369 | 0.677 | 0.119 |
| 2021-06-30 | 0.359 | 0.656 | 0.102 |
| 2021-03-31 | 0.335 | 0.648 | 0.078 |
| 2020-12-31 | 0.339 | 0.664 | 0.070 |
| 2020-09-30 | 0.339 | 0.687 | 0.131 |
| 2020-06-30 | 0.372 | 0.736 | 0.147 |
ABBV Stock Price Chart Interactive Chart >
ABBV Price/Volume Stats
| Current price | $141.99 | 52-week high | $175.91 |
| Prev. close | $138.32 | 52-week low | $106.86 |
| Day low | $137.76 | Volume | 6,612,300 |
| Day high | $142.72 | Avg. volume | 6,874,867 |
| 50-day MA | $140.88 | Dividend yield | 3.97% |
| 200-day MA | $146.38 | Market Cap | 251.05B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
Latest ABBV News From Around the Web
Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
Five Expected Dividend Increases In October 2022Every month we feature the expected dividend increases set to occur that month. Why? Since we are passionate dividend investors, we love seeing our dividend income grow without lifting a finger. Hence why we are always on the lookout for upcoming dividend increases. This article will discuss 5 expected dividend increases in October 2022. Why Dividend Increases MatterDividends are the foundation of our goal to reach financial freedom. We continuously invest in dividend growth stocks to grow our passive income. If you haven’t figured it out by now, we eat, sleep, and breathe dividends. If the goal is to produce a passive income stream that will one day cover our expenses, making sure that income stream grows is critical. Without growth, your dividend income ... |
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons WhyBased on Monday's view of an IBD-produced screen, they now include small-cap enterprise software firm Model N, lithium metal producer Albemarle, electrical equipment firm Hubbell and trendy footwear and apparel firm Deckers Outdoor. In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling. Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak. |
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023. |
Bear Market Bargains: 3 Dividend Stocks to Buy NowAll three of these stocks are attractively valued even though they're beating the market this year. |
Got $2,000? Buy These 2 Bear Market-Beating Growth StocksWith the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies. |
ABBV Price Returns
| 1-mo | N/A |
| 3-mo | -5.71% |
| 6-mo | -17.39% |
| 1-year | 34.97% |
| 3-year | 119.49% |
| 5-year | 97.29% |
| YTD | 7.86% |
| 2021 | 32.43% |
| 2020 | 27.72% |
| 2019 | 1.47% |
| 2018 | -0.96% |
| 2017 | 60.08% |
ABBV Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching ABBV
Want to do more research on AbbVie Inc's stock and its price? Try the links below:AbbVie Inc (ABBV) Stock Price | Nasdaq
AbbVie Inc (ABBV) Stock Quote, History and News - Yahoo Finance
AbbVie Inc (ABBV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...